The North America Single Use Bioreactors Market is poised for significant growth from 2024 to 2035, driven by rapid adoption in the biopharmaceutical sector and increasing investments in R&D. The market size was valued at USD 1,235 Million in 2025 and is projected to reach USD 5,870 Million by 2035, expanding at a CAGR of 15.8% over the forecast period.
The economic impact of tariffs on "North America Single Use Bioreactors Market".
Market Growth Drivers
Rising Demand for Biopharmaceuticals: The demand for monoclonal antibodies and vaccines has surged in North America, prompting biopharmaceutical companies such as Thermo Fisher Scientific to increase their production capacities. Single use bioreactors offer scalability, flexibility, and reduced risk of contamination, facilitating rapid production cycles. Companies are adopting these solutions to accelerate process development and meet stringent regulatory requirements, fueling robust market growth.
Advances in Bioprocessing Technologies: The integration of automation and digital sensor technologies in single use bioreactors by leading players like Sartorius Stedim Biotech has enhanced process monitoring and control. These advancements enable real-time data collection, improved reproducibility, and efficient scale-up for commercial manufacturing. The pursuit of operational efficiency and cost reduction by major industry players continues to drive market adoption of advanced single use systems.
Market Trends
Expansion of Modular and Closed System Designs: Market leaders such as Merck KGaA are developing modular and closed system single use bioreactors to minimize contamination risks and facilitate seamless integration into continuous bioprocessing workflows. This trend is driven by the need for flexible, scalable, and GMP-compliant production environments for next-generation biologics and cell therapies.
Growing Outsourcing to CDMOs: The outsourcing of bioproduction to Contract Development and Manufacturing Organizations (CDMOs) like Lonza is increasing across North America. CDMOs are extensively adopting single use bioreactors to cater to the rising demand for personalized medicine and small-batch biologics, as they offer reduced cleaning validation, quicker turnaround times, and lower capital investment requirements.
Market Opportunity
Expansion into Cell and Gene Therapy Production: Companies such as GE Healthcare are capitalizing on the growing demand for cell and gene therapies, integrating single use bioreactors into their manufacturing lines to accommodate small-volume, high-value production processes for advanced therapies.
Increased Adoption among Small and Mid-Size Biotechs: Single use bioreactors provide cost-effective solutions for start-ups and medium-scale biopharma companies, enabling faster process development and reducing upfront infrastructure costs, thereby expanding market reach in the region.
North America Single Use Bioreactors Market Revenue (USD Million), 2020-2035
The chart exhibits a robust upward trend in market revenue from USD 430 Million in 2020 to around USD 5,870 Million by 2035, reflecting the accelerated adoption and technological advancements in the North American region. Significant jumps are observed post-2025, attributed to increased demand for biologics, expansion by contract manufacturers, and favorable regulatory policies supporting bioprocessing innovation. The compound annual growth rate (CAGR) of 15.8% highlights the rapid expansion of single use bioreactor applications among both large pharmaceutical companies and emerging biopharma, reinforcing North America’s position as a global innovation hub for single use technologies.
Market Share by Regions (%) in 2025
In 2025, the United States leads the North America Single Use Bioreactors market, accounting for 68% of the regional share, attributed to its leading biomanufacturing infrastructure and high R&D investments. Canada follows with 18%, supported by a strong biotechnology ecosystem and government initiatives. Mexico holds 9% of the market, while Rest of North America (including countries like Bermuda and others) occupies 3%. The dominance of the U.S. is expected to continue, driven by rising production capacities among large-scale and emerging biopharma companies, and the increasingly supportive regulatory landscape for rapid bioprocessing deployment.
Recent Developments (Past 6 Months)
In April 2024, Thermo Fisher Scientific unveiled its latest HyPerforma DynaDrive single-use bioreactor platform featuring enhanced mixing and sensing technologies, tailored for streamlined process development in gene therapy and vaccine manufacturing. This launch is set to bolster their portfolio and offer unprecedented scalability for high-density cell cultures.
In March 2024, Sartorius Stedim Biotech announced a strategic partnership with Abzena, a leading CDMO, to integrate its advanced single use bioreactor solutions into Abzena’s newly expanded San Diego facility. The collaboration aims to accelerate clinical and commercial product timelines for monoclonal antibodies and novel biologics.
In May 2024, Merck KGaA (MilliporeSigma) introduced its Mobius single-use bioreactor with improved automation and digitalization capabilities. This innovation supports customers' decentralized manufacturing approaches and is engineered specifically to address new process intensification strategies in microbial fermentation and mammalian cell culture.
Press Releases